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Abstract
Background Oral anticoagulation therapy has proven beneficial impact on the prevention of thromboembolic events. How-
ever, the use of antocoagulatns also increases the risk of bleeds. To maximize the benefits and minimize the risks of the 
treatment, guidance on appropriate use of oral anticoagulants is essential. An international guideline describing relevant 
components and requirements for pharmaceutical care for patients receiving a therapy woth oral antocoagulants would 
increase the quality of care. However, recommendations on pharmaceutical care for patients on anticoagulation is lacking. 
Objective This study aims to develop an interprofessional guideline to support patients in their use of oral anticoagulation 
therapy. Method Two systematic literature searches were performed on existing guidelines on the management and interven-
tions to improve-oral anticoagulant use, to generate possible recommendations. Subsequently, an international expert panel 
with 26 pharmacists with extensive experience in clinical and/or scientific work on anticoagulation from a total of 22 Euro-
pean and 4 non-European countries was constituted. With this (geographically well distributed) expert panel, a four-round 
internet-based Delphi technique was conducted to reach consensus on their relevance. Items were ranked on a 1–10 scale 
of agreement. A median agreement score of ≥ 7.5 was considered the threshold for consensus. Levels of importance were 
rated on a 1–3 scale. Setting A global network of 26 pharmacists specialized in oral antocoagulation therapy. Main outcome 
measure Development of inter-professional guideline. Results After the four Delphi rounds 18 guideline recommendations 
were formulated. Consensus of opinion was achieved for all recommendations (median agreement: 8.5–10.0), whereas mean 
levels of importance were between 1.1 and 2.0 (SD: 0.2–0.7). The following domains were rated as most important targets for 
improving the care around oral anticoagulation: ‘INR-monitoring’, ‘Transfer of care between health care settings’, ‘Adherence 
to medication’, ‘Patient communication and engagement’, and ‘Medication reconciliation and medication review’. Conclu-
sion The 18 recommendations included in this guideline provide the base for optimization of anticoagulation care across 
different countries/healthcare systems. Future work involves translating the guideline recommendations into clinical practice. 
Once implemented, the recommendations of the guideline will support health care providers with the pharmaceutical care 
for patients on, oral anticoagulation which will improve the effective and safe use of these medicines.
Keywords Guideline development · Interprofessional guideline · Oral anticoagulations · Pharmaceutical care
Impacts on practice
• There are 18 recommendations in a new guideline, which 
provide the base for optimization of oral anticoagulation 
care for patients across different countries and health care 
systems.
• The most important elements for improving the care 
around anticoagulation are: ‘INR-monitoring’ ‘Trans-
fer of care between health care settings’ ‘Adherence to 
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medication’ ‘Patient communication and Engagement’ 
and ‘Medication Reconciliation and medication review’.
• The guideline recommendations must be translated into 
clinical practice. Multidisciplinary training, sharing 
best-practices and coaching involved health care provid-
ers, could help overcome implementation problems and 
improve success rate.
Introduction
Oral anticoagulation therapy (OAT) is one of the most com-
mon pharmacological interventions for patients with cardio-
vascular diseases. Currently, about 2% of the population in 
developed countries receives vitamin K-antagonists (VKAs) 
for the prevention of thromboembolic events. Within the last 
decade, non-vitamin K antagonists (NOACs) have emerged 
as alternatives to VKAs. Overall, oral anticoagulation pre-
scriptions are expected to increase rapidly worldwide due to 
the aging population [1, 2].
Although OAT has beneficial effects on the prevention of 
thrombotic events and improving long-term survival, the use 
of these medications is not without risk. Inhibiting the coag-
ulation cascade to reduce thrombosis consequently increases 
the risk of serious gastrointestinal and intracranial bleeds. 
Most emergency hospitalizations for recognized adverse 
drug events in older adults result from a few commonly used 
medications, with a substantial proportion of these events 
being related to VTA-use and bleeding complications being 
the most common reason for medication-related hospital 
admissions [3–6].
Due to the serious nature of the drug-related problems 
(DRPs) associated with OAT, health care professionals and 
patients need to be actively supported to ensure safe and 
effective medication use. Several studies have illustrated 
that inappropriate prescribing, monitoring, and administra-
tion of OAT occur frequently. Oral anticoagulants are often 
underdosed, inadequately monitored, inappropriately stored, 
and not taken as prescribed, all of which contribute to the 
increased risk for DRPs [7–10].
Both the European Heart Rhythm Association (EHRA) 
and the European Society of Cardiology (ESC) included 
updated adequate structured follow-up of OAT-patients 
as essential for patient safety in the updated versions of 
their guidelines [11, 12]. Various health care providers are 
involved in providing anticoagulation care, including physi-
cians, nurses and pharmacists. Efficient multidisciplinary 
collaboration and communication is therefore essential to 
ensure patient safety. Nonetheless, this collaboration is often 
suboptimal which can exaggerate uncertainties including 
confusion in the division of responsibilities and frequent 
miscommunications [13].
An international guideline describing relevant compo-
nents and requirements for adequate structured follow up 
for patients receiving oral anticoagulation therapy would 
increase the quality of pharmaceutical care for patients on 
OATS, foster consistency in the provision of pharmaceuti-
cal care including continuity of care [11, 12, 14]. However, 
an interprofessional guideline to support medication use in 
patients using OAT is currently lacking.
Aim of the study
This study aims to develop an interprofessional guideline to 
support patients in their use of Oral anticoagulation therapy 
(OAT).
Ethics approval
An ethics approval for the described processes was not 
required. All participants of the Delphi-procedure agreed to 
par-ticipate in the research. The data are reported on group-
level, so individual participants can not be identified from 
the results.
Method
Study design
To obtain insight into existing recommendations on the man-
agement of patients receiving OAT and evidence on inter-
ventions to optimize medication use in this patient group, 
two systematic literature searches were performed. The first 
aimed at critically appraising existing guidelines, standards, 
and quality measures on OAT, whereas the second evaluated 
the impact of interventions to improve OAT-use. Combining 
the results of the two reviews, a list of potential domains 
to be reflected upon in the guideline were subjected to a 
consensus method. Accordingly, an internet-based Delphi 
exercise was conducted with international OAT-experts, to 
develop internationally applicable and acceptable interpro-
fessional guideline recommendations to support patients 
receiving OAT (Fig. 1).
Literature searches
Existing guidelines
To obtain insight into existing guidelines on the manage-
ment of OAT patients, a literature search was conducted in 
PUBMED, EMBASE, CINAHL, the Cochrane library, and 
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Global Health searched up until March 2015. In this litera-
ture review, OAT guidelines, standards, and quality meas-
ures published up until March 2015, and with full-text writ-
ten in English, were included. The detailed search strategy 
can be found in “Appendix 1” section.
A manual query was performed using reference lists of 
included studies. In order not to exclude potential ‘grey 
literature’, websites of international societies and health 
care organizations were searched to retrieve additional 
OAT-related guidelines, treatment standards, and quality 
measures.
Full-text manuscripts, fulfilling the above inclusion crite-
ria, were evaluated using the methodological tool, AGREE 
II to assess quality [15]. Only guidelines receiving a high 
score in the overall quality assessment (i.e., 4–7) were used 
for further analyses. Of the included documents, all rec-
ommendations and other information related to OAT were 
extracted. This information was organized into a “grid” 
according to the domains and standards of the Foundation 
Pharmacy Framework of the Royal Pharmaceutical Society 
[16]. The design (and results) of this literature review will 
be published separately.
Interventions to optimize OAT‑use
To obtain insight into the current evidence on interventions 
to improve OAT-use, a second systematic literature search 
was conducted. PUBMED (including MEDLINE) and 
EMBASE were searched up until March 2016. The search 
strategy included terms related to pharmaceutical care inter-
ventions combined with OAT-use. The detailed search strat-
egy can be found in “Appendix 1” section.
Studies were eligible for inclusion if they focussed on 
pharmaceutical care interventions for patients receiving 
OAT (NOACs or VKAs), and compared the effectiveness 
(e.g., time-in-therapeutic range (TTR)) and/or safety (e.g., 
bleeding, thromboembolic events) of the pharmaceutical 
care intervention with usual care. Two reviewers indepen-
dently performed title/abstract and full-text selection, quality 
assessment (using the STROBE statement), as well as data 
extraction of the eligible studies. The design (and results) of 
this systematic literature review will be published separately.
Subsequently, the interventions found to improve OAT-
use were linked to existing guideline recommendations as 
retrieved in the first literature review. Based on this com-
bination of results, domains of interprofessional OAT-care 
potentially relevant for inclusion in the interprofessional 
guideline to support patients receiving oral anticoagulation 
therapy were identified.
Delphi exercise
The Delphi exercise was initiated in March 2016 and com-
prised four internet-based rounds with an international 
expert panel as well as two broader consultation rounds 
of international ‘key opinion leaders (KOLs)’ and global 
umbrella organizations, all of which were finalised by 
November 2016.
The expert panel of the first Delphi exercise was com-
prised of the ‘International Pharmacists for Anticoagulation 
Care Taskforce (iPACT)’. iPACT consists of 26 pharmacists 
with extensive experience in clinical and/or scientific work 
on OAT from a total of 22 European and 4 non-European 
countries. In the selection procedure for the experts it was 
assured that all continents were represented, the European 
experts were geographically well distributed and experts 
with knowledge on specific relevant subthemes (adherence 
(e.g. IA, FA), monitoring (e.g. JP, SA), education (FA, IA, 
SR)) were represented. The project team, consisting of two 
independent researchers (NW and ND) and a project leader/
pharmacist (BvdB). All electronic questionnaires were 
Two literature searches
Exisng guidelines &intervenons to 
improve OAT-use
Delphi round 1
Vienna, March 2016
N=17 iPACT-members
Online KOL consulta	on
June 2016
N=85 KOLs
First dra 18 guideline 
recommendaons
20 guideline domains and 
core components
Adapted dra 18 guideline 
recommendaons
Online Delphi round 2
August 2016
N=26 iPACT-members
Online Delphi round 3
September 2016
N=26 iPACT-members
Online Delphi round 4
October 2016
N=26 iPACT-members
Final dra 18 guideline 
recommendaons
Adapted dra 18 guideline 
recommendaons
Consulta	on umbrella 
organisa	ons 
November2016
Final set of guideline 
recommenda	ons 
16 potenally relevant 
domains
Fig. 1  Overview of our Delphi technique
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constructed using ‘Google forms’ and two email reminders 
were issued to the panel members each round.
In accordance with previous research, mean and median 
levels of agreement were reported and a threshold for con-
sensus of 75% was adopted. [17, 18] A consensus was 
achieved if the median level of agreement of the expert panel 
members on a certain topic was 7.5 or higher [17, 18].
In Fig. 1, an overview of our Delphi exercise is provided. 
Delphi round 1 comprised a 1-day meeting with the iPACT 
expert panel in Vienna (Austria). In semi-structured group 
discussions, the domains from the literature searches were 
discussed and revised, and corresponding core components 
(e.g., how, when, and by whom should the OAT-care activity 
be performed) were formulated.
The results of Delphi round 1 were verified by a broader 
international online expert panel. For this purpose, iPACT 
members provided nominations for KOLs in each of their 
respective countries. Nominations were provided across 
even different anticoagulation-related disciplines: pharma-
cists, physicians, nurses, pharmaceutical companies, patient 
organizations, anticoagulation services, and general practi-
tioners. Based on their input, the project team translated the 
domains and core components into a first draft of guideline 
recommendations on interprofessional OAT-care.
In Delphi round 2, an online questionnaire was con-
structed to present the first draft of the guideline recom-
mendations to iPACT-panel members. In addition to solic-
iting suggestions on complementing and/or rephrasing the 
recommendations, experts were asked to rate their level of 
agreement with (the content and relevance of) each recom-
mendation on a 10-point Likert scale (1 = completely disa-
gree’ to 10 = completely agree’) as was done in previous 
studies [17, 18].
In the online questionnaire of Delphi round 3, we first 
provided the iPACT-expert panel members with feedback 
on results of Delphi round 2. This feedback was provided 
by means of bar graphs of panel ratings and information on 
the mean/median level of agreement per recommendation. 
iPACT-experts were then asked to rate their level of agree-
ment with the adapted recommendations on a 10-point scale. 
Panel members could also provide suggestions for comple-
menting and rephrasing the recommendations.
In the final Delphi round 4, we again provided the iPACT-
panel members with feedback on the results of the previ-
ous round. In addition, they were asked to rate each of the 
recommendations on their level of importance using a scale 
of 1–3: 1=’A must have for the final set of recommenda-
tions’; 2=’Would be nice to have in the final set of recom-
mendations’; 3=’Is not important in a final set of recom-
mendations’ [17, 18]. Further, there was the possibility 
to provide final remarks on the proposed wording of the 
recommendations.
As a last step, in a second broader consultation round the 
final draft of recommendations were presented to several 
umbrella organizations relevant for OAT-care (i.e., Ameri-
can Society of Health-system Pharmacists (ASHP), Antico-
agulation Europe, American College of Clinical Pharmacy 
(ACCP), European Association of Hospital Pharmacists 
(EAHP), EHRA, European Stroke Association (ESA), ESC, 
European Society of Clinical Pharmacy (ESCP), European 
Society for Patient Adherence, COMpliance, and Persistence 
(ESPACOMP), International Society on Thrombosis and 
Haemostasis, and Pharmaceutical Group of the European 
Union (PGEU)), as suggested by iPACT-experts. By means 
of a final online questionnaire we asked contact persons of 
these organizations to provide us with their feedback on the 
guideline.
Results
Literature searches
Existing guidelines
For the first literature search on existing guidelines on the 
management of OAT patients, 6777 titles and abstracts were 
screened, of which 30 full-text articles were included in the 
final selection of studies. The preliminary framework, to 
which the overview of existing guideline recommendations 
was translated, resulted in 12 standards subdivided in 45 
dimensions for interprofessional care application in patients 
receiving OAT.
Interventions to improve OAT‑use
Of the 11,171 titles and abstracts screened, 125 full-text arti-
cles were included in the final selection of studies. All rel-
evant information on interventions to improve OAT-use was 
extracted. From the results of this literature review, 12 differ-
ent interventions (e.g., patient education, self-management, 
medication review, medical training) were identified, each 
having a substantial impact on the effectiveness and safety 
of OAT as demonstrated by, for example, a greater TTR and/
or fewer bleeding and thromboembolic events.
In combining the results of both literature searches, every 
intervention found to improve oral anticoagulant use could 
be linked to one or more existing guideline recommenda-
tions as found in the first literature search. Based on this 
combination of results, and without rejecting any guideline 
or intervention, 16 unique domains potentially relevant 
for interprofessional care in OAT-patients were eventually 
extracted by the project team. These unique domains pro-
vided the base for the Delphi exercise (Table 1). 
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Delphi round  1 Seventeen members (65%) of the iPACT-
expert panel attended the 1-day meeting in Vienna. During 
this meeting, the 16 domains as identified in the literature 
searches were critically revised in semi-structured group 
discussions. After both plenary and subgroup discussions, a 
final set of 20 domains relevant for interprofessional OAT-
care was determined. Three additional domains were added 
to the original set based on expert opinion: ‘Lifestyle and 
cultural-specific aspects’, ‘Screening’, and ‘Patient com-
munication and engagement’. Further, the domain ‘Phar-
macogenetic dosing’ was divided into ‘Pharmacogenom-
ics’ and ‘Metabolic monitoring’, resulting in the final total 
of 20 domains. In addition, several titles of domains were 
adapted (e.g., ‘Adherence-interventions’ was changed into 
‘Adherence to medication’) to better reflect clinical practice 
of interprofessional OAT-care (Table 2).
During the second half of the meeting, panel members 
split into six subgroups and discussed the core components 
of the 20 domains (e.g., how, when, by whom should the 
intervention to improve OAT-use be performed). To enable 
additional reflection, after the in-person meeting these core 
components were further enhanced and clarified by email. 
This allowed for any non-attendees to be involved in the 
process. They had the opportunity to also reflect on the iden-
tified set of domains and core components.
Consultation of international key opinion leaders To verify 
the results of Delphi round 1, we approached 85 KOLs of 14 
(both European and non-European) countries. In total, 26 
KOLs (30.6%) responded to our online questionnaire, and 
provided suggestions for complementing and/or rephrasing 
of our 20 domains and core components.
Based on KOLs’ feedback, the core components of the 
domain ‘Process management’ were integrated into the 
domains of ‘Governance’ and ‘Pharmacy workforce’, as 
these were highly overlapping. In addition, the domain 
‘Metabolic monitoring’ was deleted as its core components 
could be integrated in the ‘Therapy plan’ domain.
Online Delphi round 2 Of the 26 iPACT-panel members, 20 
completed the online questionnaire (response rate: 76.9%) 
of Delphi round 2. The mean level of agreement ranged 
from 7.6 to 9.2 [SD: 0.8–2.6]. The median level of agree-
ment varied between 8.0 and 10.0 for all guideline recom-
mendations, indicating that all recommendations met the 
criteria for inclusion in this second round (Appendix 2 of 
electronic supplementary material). Comments on comple-
menting and rephrasing of the guideline recommendations 
were built into the next version.
Table 1  Input for Delphi round 
1: 16 domains relevant for 
interprofessional OAT-care, 
based on the literature reviews
OAT oral anticoagulation therapy
Domains for interprofessional oat-care
1. Adherence-interventions 7. Treatment plan 12. Transfer of care 
between health care 
settings
2. Shared-care/self-management 8. Pharmacogenetic dosing 13. Medical training
3. Patient education 9. Pharmacotherapeutic surveillance 14. Process management
4. Anticoagulation pharmacist/nurse 10. INR-monitoring, patient self-test-
ing, point-of-care testing
15. Pharmacy workforce
5. Telemedicine 11. Medication supply 16. Governance
6. Medication review/clinical rules
Table 2  Result of Delphi round 1: 20 domains relevant for interprofessional OAT-care, as determined by the iPACT-expert panel
OAT oral anticoagulation therapy
Domains for interprofessional oat-care
1. Adherence to medication 8. Medication reconciliation and 
medication review
15. Medication supply
2. Lifestyle and cultural-specific aspects 9. Therapy plan 16. Transfer of care between health care settings
3. Patient communication and engagement 10. INR-monitoring, patient self-
testing, point-of-care testing
17. Governance
4. Patient education 11. Screening 18. Continuing professional development
5. Shared-care/self-management 12. Pharmacovigilance 19. Pharmacy workforce
6. Anticoagulation pharmacist/nurse 13. Pharmacogenomics 20. Process management
7. Telemedicine 14. Metabolic monitoring
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Online Delphi round  3 Similarly, 20 out of 26 (76.9%) 
iPACT-experts completed the online questionnaire of Del-
phi round 3, which included feedback on the results of 
Delphi round 2. The mean level of agreement with the 18 
adapted guideline recommendations ranged from 7.4 to 9.4 
[SD: 0.7–2.0]. Experts’ comments on complementing and 
rephrasing were built into an adapted draft of the guideline 
recommendations.
Online Delphi round  4 In this final Delphi round, 20 out 
of 26 (76.9%) online questionnaires were completed. The 
mean level of importance—as rated by the experts on a 1–3 
scale—ranged from [1.1 to 2.0], with standard deviations 
ranging between [0.2 and 0.7]. There was one final com-
ment, which the project team processed into the final draft 
of the guideline recommendations.
Second consultation round  of  global umbrella organiza‑
tions The input of the broader consultation of different 
umbrella organizations relevant for OAT-care, was built into 
the final set of guideline recommendations.
In Table 3, the Top 5 interprofessional guideline rec-
ommendations to support patients receiving oral antico-
agulation therapy are presented. Specifications of these 
recommendations are listed in Appendix 2 of electronic sup-
plementary material, in which the final set of 18 guideline 
recommendations is presented. In Appendix 2 of electronic 
supplementary material, the main recommendation, speci-
fications, corresponding mean/median level of agreement 
(LoA) of Delphi round 3, and level of importance (LoI) of 
Delphi round 4 is presented.
Discussion
In this four-round internet-based Delphi exercise (preceded 
by two systematic literature searches), 18 recommendations 
for better and safer use of OATS were formulated. These 
recommendations were formulated by a multidisciplinary 
team across different countries/healthcare systems which 
reached consensus on all recommendations. The Top 5 
interprofessional guideline recommendations comprised 
‘INR-monitoring’, ‘Transfer of care between health care 
settings’, ‘Adherence to medication’, ‘Patient communica-
tion and Engagement’, and ‘Medication Reconciliation and 
medication review’ (details listed in Table 3 and Appendix 2 
of electronic supplementary material).
Compared to the other recommendations, expert consen-
sus on the agreement/importance ratings of ‘Pharmacoge-
netic assessment’ and ‘Screening’ varied greatly. This could 
be explained by the fact that both topics are currently subject 
to debate and countries differ in their opinion on whether to 
incorporate these interventions in standard clinical OAT-
care. For each recommendation, the median consensus 
threshold of ≥ 7.5 was reached after Delphi round 2, so they 
were included in the final guideline.
In translating our guideline recommendations into front-
line clinical practice, two important prerequisites should be 
taken into account. First, with the guideline recommenda-
tions we aim to address interprofessional, multidisciplinary 
OAT-care rather than care provided by any specific health-
care professional, such that recommendations are applicable 
to the broader field of OAT-care. Second, we acknowledge 
the fact that important elements of OAT-care may differ 
between countries and local contexts. Notwithstanding, the 
Delphi technique included representation from many coun-
tries and a variety of healthcare professionals and patient 
care organisations in order to mitigate for these differences.
Strengths and limitations
The Delphi exercise is a well-recognized, structured process 
designed to achieve group-consensus on certain topics. A 
Delphi exercise include its ability to easily involve individual 
experts across different geographical and clinical settings. 
Further, subject anonymity is an important prerequisite of 
Table 3  Top 5 interprofessional guideline recommendations to support patients receiving oral anticoagulation therapy
Main recommendation
1. INR-monitoring In patients using VKAs, the international normalized ratio (INR) should be monitored 
regularly to ensure the safety and effectiveness of oral anticoagulation therapy (OAT)
2. Transfer of care between health care settings Accurate information about patients’ OAT, including current medications, should be trans-
ferred accurately between different health care settings to ensure seamless care
3. Adherence to medication In patients using oral anticoagulation medication, adherence to and persistence with 
therapy should be assessed and supported. Patients and their caregivers should be edu-
cated on adherence
4. Patient communication and engagement Communication with and the involvement of patients and their caregivers should be con-
sidered an integral component of safe and effective interprofessional OAT-care
5. Medication reconciliation and medication review In OAT-patients, medication reconciliation and medication review should be performed on 
a regular basis to ensure the safe, effective, and clinically appropriate use of medication
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the Delphi, reducing the effects of dominant individuals on 
a group-based process [17, 19].
An additional advantage of our Delphi exercise is the 
online procedure we used. Panel engagement over the 
four online survey rounds was high, with response rates of 
> 70% and a large volume of comments and feedback being 
reported in every round. This advantage of online data col-
lection have been reported previously [20].
Several limitations of the Delphi exercise should also be 
acknowledged. First, given the internet-based character of 
the Delphi, there was an inability for expert panel mem-
bers to meet and discuss uncertainties or ambiguities in 
the construction or wording of the questionnaires. Another 
weakness of this consensus methodology is that the suc-
cess of the Delphi process depends on the panel chosen. 
There are no universally agreed criteria for the selection 
of experts, nor agreement on the minimum or maximum 
number of members needed. When the iPACT-expert panel 
was formed, specific attention was paid to a representative 
distribution across countries. The final panel comprised only 
of pharmacists, as pharmacists are fully specialized in phar-
maceutical care. One might argue that this could hamper 
the generalizability of the guideline to other OAT health 
care professionals. Therefore, we verified our results in 
two broader consultation rounds with KOLs from different 
anticoagulation-related disciplines and umbrella organiza-
tions. As these two rounds did not result in changes to the 
recommendations, our guideline seems to be generalizable 
to other disciplines as well.
Conclusion
In the current Delphi exercise an interprofessional guideline 
to support patients receiving oral anticoagulation therapy 
was developed. The 18 recommendations included in this 
guideline provide the base for optimization of OAT-care for 
patients across different countries and health care systems. 
Future work involves translating the guideline recommenda-
tions into clinical practice with an assessment on the impact 
to patient care.
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Appendix 1
Search strategies
Search strategy for the literature review on existing 
guidelines
The following keywords were used: “guideline”, “clinical 
practice guideline”, “treatment guideline”, “guidance”, “rec-
ommendation”, “standard of care”, “quality measure”, and 
“oral anticoagulation” “Standards” OR “Standard”[Mesh] 
OR Pharmaceutical  care” OR Pharmaceutical 
Services”[Mesh] OR “Pharmaceutical service” OR “Phar-
maceutical services” OR “Quality” OR “Quality”[Mesh] OR 
“Measure” OR “Measure”[Mesh] OR “Quality Measure” 
OR “Quality Measure”[Mesh], Educational OR Education 
OR “Pharmacist Education as Topic”[Mesh] OR “Health 
Education”[Mesh] OR “Pharmacist knowledge”[Mesh] 
OR Knowledge OR “Anticoagulant care” OR “Antico-
agulation care” OR “Anticoagulation services” OR “Anti-
coagulation service” OR “Patient safety” OR “Patient 
safety”[Mesh], “Pharmacy” OR “Pharmacy”[Mesh] OR 
Pharmacist[Mesh] OR Pharmacist[Text Word] OR “Phar-
maceutical Services”[Mesh], “Atrial” OR “Atrial”[Mesh] 
OR “Fibrillation” OR “Fibrillation”[Mesh] OR “AF” OR 
“AF”[Mesh]
AND
Anticoagulants[Mesh] OR “Oral anticoagulants” OR 
“Oral anticoagulant” OR “Oral anticoagulant”[Text Word] 
OR “Oral anticoagulants”[Text Word] OR Phenindione OR 
Phenindione[Mesh] OR Phenindione[Text Word]“Vitamin 
K antagonist” [Mesh] OR “Vitamin K antagonist”[Text 
Word] OR Warfarin OR Warfarin[Mesh] OR Warfarin[Text 
Word] OR Acenocoumarol OR Acenocoumarol[Mesh] 
OR Acenocoumarol[Text Word] OR “Non vitamin K 
antagonist”[MESH] OR “Non vitamin K antagonist [Text 
Word] OR Direct Oral Anticoagulant [MESH] or Direct 
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Oral Anticoagulant [Text word] OR Apixaban Or Apixa-
ban [Supplementary Concept] OR Apixaban[Text Word] 
OR Dabigatran OR Dabigatran[Mesh] OR Dabigatran[Text 
Word] OR Edoxaban OR Edoxaban [Supplementary Con-
cept] OR Edoxaban[Text Word] OR Rivaroxaban OR 
Rivaroxaban[Mesh] OR Rivaroxaban[Text Word]
Search strategy for the literature review on interventions 
to optimize OAT‑use
R i v a r o x a b a n  O R  R i v a r o x a b a n [ M e s h ]  O R 
Rivaroxaban[Text Word] OR Apixaban Or Apixaban 
[Supplementary Concept] OR Apixaban[Text Word] 
OR Edoxaban OR Edoxaban [Supplementary Con-
cept] OR Edoxaban[Text Word] OR Acenocoumarol 
OR Acenocoumarol[Mesh] OR Acenocoumarol[Text 
Word] OR Phenprocoumon OR Phenprocoumon[Mesh] 
OR Phenprocoumon[Text Word] OR Warfarin OR 
Warfarin[Mesh] OR Warfarin[Text Word] OR Dabi-
gatran OR Dabigatran[Mesh] OR Dabigatran[Text 
Word] OR Ximelagatran OR Ximelagatran [Supple-
mentary Concept] OR Ximelagatran[Text Word] OR 
Anticoagulants[Mesh] OR “Oral anticoagulants” OR “Oral 
anticoagulant” OR “Oral anticoagulant”[Text Word] OR 
“Oral anticoagulants”[Text Word] OR Phenindione OR 
Phenindione[Mesh] OR Phenindione[Text Word]
AND
(“Observat ional  Study” OR “Observat ional 
Study”[Publication Type] OR “Observational Stud-
ies as Topic”[Mesh] OR “Randomized Controlled 
Trial”[Publication Type] OR “Randomized Controlled 
Trial” OR “Randomised controlled trials” OR “Randomized 
Controlled Trials as Topic”[Mesh] OR “Controlled Clinical 
Trial” [Publication Type] OR “Controlled Trial” OR “Con-
trolled trials” OR “Non-Randomized Controlled Trials as 
Topic”[Mesh] OR “Retrospective study” OR “Retrospec-
tive Studies”[Mesh] OR “Prospective study” OR “Prospec-
tive Studies”[Mesh] OR “Longitudinal Studies”[Mesh] OR 
“Longitudinal study” OR “Longitudinal studies” OR “cohort 
study” OR “cohort studies” OR “Cohort Studies”[Mesh])
AND
“Medication review” OR “Medication reviews” 
OR “Drug Utilization”[Mesh] OR “Drug Utiliza-
tion Review”[Mesh] OR Pharmacogenetic* OR 
Pharmacogenetics[Mesh] OR Genotype OR Genetic* OR 
Adherence OR Medication Adherence[Mesh] OR Persis-
tence OR Compliance OR”Patient Compliance”[Mesh] OR 
Pharmacist* OR Pharmacist[Mesh] OR Pharmacist[Text 
Word] OR “Pharmaceutical Services”[Mesh] OR “Pharma-
ceutical service” OR “Pharmaceutical services” OR Educa-
tional OR Education OR “Patient Education” OR “Patient 
Education as Topic”[Mesh] OR “Health Education”[Mesh] 
OR “Patient medication knowledge”[Mesh] OR Knowledge 
OR “Pharmaceutical care” OR “Patient care” OR “Point-of-
Care Systems”[Mesh] OR “Point-of-care” OR “Anticoagu-
lant care” OR “Anticoagulation care” OR “Anticoagulation 
services” OR “Anticoagulation service” OR “Drug-Related 
Side Effects and Adverse Reactions”[Mesh] OR “Patient 
counseling” OR continuation OR discontinuation OR Moni-
toring OR Self-management OR “medication errors” OR 
“medication error” OR “medication errors”[MeSH] OR 
“Patient safety” OR “Patient safety”[Mesh]
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